A number of Swedish and international institutional and professional investors, including a company closely associated with Board member Anders Bladh, participated in the Directed Share Issue. Through the Directed Share Issue, KDventures AB raises approximately SEK 23.9 million before transaction costs.

The Directed Share Issue and use of proceeds

The Directed Share Issue, comprising a total of 99,516,667 B shares, is carried out with deviation from the shareholders’ preferential rights, based on the authorization granted to the Board of Directors by the Annual General Meeting held on 12 May 2026.

The subscription price of SEK 0.24 per B share and the total number of 99,516,667 new B shares have been determined through an accelerated bookbuilding procedure directed to Swedish and international institutional and professional investors. Through the Directed Share Issue, the Company raises gross proceeds of approximately SEK 23.9 million before deduction of issue costs.

The proceeds from the Directed Share Issue are intended to be used to finance the Company’s acquisition of Rosetta Capital IV Sàrl’s shares in KDev Investments AB, which was announced by the Company in a press release on 17 June 2026.

The acquisition is intended to be financed through a combination of the Directed Share Issue and the Company’s available cash.

Deviation from the shareholders’ preferential rights

The Board of Directors has carefully considered the possibility to raise capital through a rights issue and makes the assessment that there are currently several reasons why it is more beneficial for the shareholders to raise capital through a directed share issue. A rights issue would take significantly longer to execute, which could have a negative impact on the Company. In addition, a rights issue could require underwriting commitments from an underwriting syndicate, which could entail higher costs and/or greater dilution and a rights issue would likely have to be carried out at a lower subscription price based on the discount levels applied in recent rights issues. Furthermore, the Company wishes to expand and strengthen its base of institutional and professional shareholders, with the aim of strengthening the liquidity of the Company's share.

The Board of Directors' assessment is thus that an issue of shares with deviation from the shareholders' preferential rights is the most suitable alternative.

As the subscription price in the Directed Share Issue has been determined through an accelerated bookbuilding procedure, the Board of Directors assesses that the market terms of the subscription price have been ensured.

Share capital and number of shares

Through the Directed Share Issue, the total number of B shares will increase by 99,516,667, from 656,972,867 B shares to 756,489,534 B shares, and the share capital will increase by SEK 995,166.67, from SEK 6,595,281.28 to SEK 7,590,447.95. The number of A shares remains unchanged at 2,555,261. The Directed Share Issue entails a dilution effect of approximately 13.16 percent based on the total number of B shares in KDventures AB after the Directed Share Issue.

Advisers

Redeye Corporate Finance AB is the financial adviser to KDventures AB in connection with the Directed Share Issue, and Cirio Advokatbyrå AB is the legal adviser. Nordic Issuing AB acts as issuing agent in connection with the Directed Share Issue.

For further information, please contact:

Viktor Drvota, CEO, KDventures AB

Tel: +46 73 982 52 02, e-mail: viktor.drvota@kd-ventures.com

Johan Dighed, General Counsel and Deputy CEO, KDventures AB

Tel: +46 70 207 48 26, e-mail: johan.dighed@kd-ventures.com

This information is information that KDventures AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact persons, on 18 June 2026 at 08:15 CEST.

About KDventures AB

KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specializing in life science. The Company identifies and invests in innovative pharmaceutical projects and medical technology products from leading research institutions in the Nordic region. Through a diversified portfolio across different stages of development, professional due diligence and active board involvement, KDventures AB creates value from early-stage research to commercialization. The Company offers investors exposure to both listed and unlisted life science projects with potential for significant value appreciation.

For more information: www.kd-ventures.com

Important information

This press release and the information herein is not for publication, release or distribution, in whole or in part, directly or indirectly, in or into the United States, Australia, Belarus, Canada, Japan, New Zealand, Russia, Switzerland, Singapore, South Korea or South Africa or any other state or jurisdiction in which publication, release or distribution would be unlawful or where such action would require additional prospectuses, filings or other measures in addition to those required under Swedish law.

This press release is for informational purposes only and does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire, or subscribe for, any of the securities mentioned herein (collectively, the “Securities”) or any other financial instruments in the Company. Offers will not be made to, and subscriptions will not be approved from, subscribers or persons acting on behalf of subscribers, in any jurisdiction where applications for such subscription would contravene applicable laws or regulations, or would require prospectuses, filings, or other measures in addition to those required under Swedish law. Measures in violation of the restrictions may constitute a breach of relevant securities laws.

None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered, distributed or otherwise transferred, directly or indirectly, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with other applicable securities laws. There will not be any public offering of any of the Securities in the United States.

In the United Kingdom, this press release is directed only at, and communicated only to, persons who are qualified investors as defined in paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 who are (i) persons who fall within the definition of "investment professional" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons who fall within article 49(2)(a) to (d) of the Order, or (iii) persons to whom it may otherwise be lawfully communicated (all such persons referred to in (i), (ii) and (iii) above together being referred to as "Relevant Persons"). This press release must not be acted on or relied on by persons in the UK who are not Relevant Persons.

This press release does not constitute an investment recommendation. The price and value of securities and any income derived from securities may go down as well as up, and you may lose your entire investment. Past performance is not an indication of future performance. The information in this press release may not be relied upon as an indication of future performance.

This press release contains certain information reflecting the Company’s current view of future events as well as financial and operational development. Words such as “intends”, “assesses”, “expects”, “may”, “plans”, “estimates” and other expressions which imply indications or predictions regarding future development or trends, and which are not based on historical facts, constitute forward-looking information and reflect the Company’s beliefs and expectations and involve a number of risks, uncertainties and assumptions that may cause actual events and results to differ materially from any anticipated future events or performance expressed or implied by the forward-looking statement. The information in this press release may change without prior notice and, except as required by applicable law, the Company undertakes no responsibility or obligation to publicly update or review any of the forward-looking statements herein, nor does it intend to do so. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.

In order to comply with the product governance requirements contained in: (a) Directive 2014/65/EU of the European Parliament and of the Council on markets in financial instruments, as consolidated (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593, which supplements MiFID II; and (c) national implementing measures (together, the “MiFID II Product Governance Requirements”), and to disclaim any extra-contractual, intra-contractual or other liability to which any “manufacturer” (within the meaning of the MiFID II Product Governance Requirements) may otherwise be subject, the shares of the Company have been subject to a product approval process, which has determined that these shares are: (i) suitable for a target market consisting of retail investors and investors meeting the criteria of professional clients and eligible counterparties, as defined in MiFID II (the “Positive Target Market”); and (ii) suitable for distribution through all distribution channels permitted under MiFID II. Distributors should note that: the price of the Company’s shares may fall and investors may lose all or part of their investment; the Company’s shares are not subject to any guarantee of return or capital protection; and an investment in the Company’s shares is only suitable for investors who are not in need of a guaranteed return or capital protection and who (alone or with the assistance of an appropriate financial or other adviser) are capable of evaluating the merits and risks of such investment and have sufficient resources to bear the losses that may result from such investment. Conversely, an investment in the shares of the Company is not suitable for investors who need full capital protection or full repayment of the amount invested, cannot bear any risk or require a guaranteed or predictable return (the “Negative Target Market”, and together with the Positive Target Market, the “Target Market”). The Target Market assessment is without prejudice to any other requirements regarding contractual, legal or regulatory sales restrictions in relation to the Directed Share Issue.

For the avoidance of doubt, the Target Market assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, acquire, or take any other action whatsoever with respect to the Company’s shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Company’s shares and for determining appropriate distribution channels.